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Simple Summary: In-time diagnosing ovarian cancer, intractable cancer that has no symptoms can
increase the survival of women. The aim of this study was to discover biomarkers from liquid biopsy
samples using multi-omics approach, metabolomics and proteomics for the diagnosis of ovarian
cancer. To verify our biomarker candidates, we conducted comparative analysis with other previous
published studies. Despite the limitations of non-invasive samples, our findings are able to discover
emerging properties through the interplay between metabolites and proteins and mechanism-based
biomarkers through integrated protein and metabolite analysis.
Abstract: The 5-year survival rate in the early and late stages of ovarian cancer differs by 63%.
In addition, a liquid biopsy is necessary because there are no symptoms in the early stage and tissue
collection is difficult without using invasive methods. Therefore, there is a need for biomarkers to
achieve this goal. In this study, we found blood-based metabolite or protein biomarker candidates
for the diagnosis of ovarian cancer in the 20 clinical samples (10 ovarian cancer patients and 10
healthy control subjects). Plasma metabolites and proteins were measured and quantified using mass
spectrometry in ovarian cancer patients and control groups. We identified the differential abundant
biomolecules (34 metabolites and 197 proteins) and statistically integrated molecules of different
dimensions to better understand ovarian cancer signal transduction and to identify novel biological
mechanisms. In addition, the biomarker reliability was verified through comparison with existing
research results. Integrated analysis of metabolome and proteome identified emerging properties
difficult to grasp with the single omics approach, more reliably interpreted the cancer signaling
pathway, and explored new drug targets. Especially, through this analysis, proteins (PPCS, PMP2,
and TUBB) and metabolites (L-carnitine and PC-O (30:0)) related to the carnitine system involved in
cancer plasticity were identified.
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1. Introduction
Ovarian cancer is one of the fatal gynecological cancers, and the 5-year survival rate is
approximately 47.7% which is the 8th lowest among cancers from 2008 to 2014 [1]. It is the fifth most
common cause of cancer deaths in the United States, and about 14,000 women die from it each year [2].
Asymptomatic cancer disease progression occurs in the early stages of ovarian cancer with a 5-year
survival rate of 92%, and symptoms appear in the later stages with a 5-year survival rate of 29% [3,4].
Liquid biopsy used to diagnose ovarian cancer is essential due to the difficulty of collecting ovarian
tissue without using invasive means. Currently, screening with plasma cancer antigen 125 (CA-125)
appears practical, but establishing the value of screening is challenging [3,4]. A novel biomarker for
diagnosing the cancer is needed, and for this purpose, we applied two-omics, proteomic and metabolic,
approaches to clinical plasma samples from the same person.
Tumor metabolism alterations were influenced by switching the activity of related enzymes
or rearranging carcinogenic pathways induced by the genetic mutation or epigenetic changes [5–7].
Based on this assumption, recent comparative studies of ovarian cancer patients and healthy female
volunteers have been conducted for the discovery of biomarkers in the tissue [8], plasma [9–11],
and both [12]. Whereas, in recent years, there have been various studies related to ovarian cancer
using proteomics, and among them were studies of serological markers discovery [13–16], studies of
differences in biological mechanisms based on differential expression between normal and tumor
tissues [17–20], and studies to integrate them with the genome [21–25]. Unfortunately, the combined
study of metabolites and proteins in blood has not yet been investigated for ovarian cancer.
In this preliminary study, we carried out flow injection analysis (FIA) or LC–MS/MS profiling to
discover blood-based metabolite or protein biomarker candidates for the diagnosis of ovarian cancer
and we presented an analysis of the plasma metabolome and proteome in the 20 clinical samples
(10 ovarian cancer and 10 female control subjects). In addition to independent protein and metabolite
analysis, the emerging results were obtained through integrated analysis, and this information was
useful for interpreting cancer signaling pathway activity and the exploration of new drug targets.
2. Results
2.1. Study Design
We collected plasma from 10 ovarian cancer (OC) patients and 10 female healthy controls (HC)
and analyzed the proteome and metabolome of the samples. The demographic characteristics of the
study attendants are summarized in Table 1. The mean (standard deviation) age of the subjects was
55.6 (12.5) years among the healthy female subjects and 59.7 (15.4) years in the ovarian cancer patients;
this difference was not significant (p = 0.511). The patients with ovarian cancer had serous histological
subtypes of stages 3 and 4.
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Table 1. Demographic and clinical variables of the clinical samples.
Variable Healthy Controls(n = 10)
Ovarian Cancer Patients
(n = 10) p-Value
1
Age (years) 55.5 ± 12.5 59.7 ± 15.4 0.511
Histology (n) NA 10 -
Serous NA 10 -
FIGO 2 - - -
1 a - 0 -
1 b - 0 -
1 c - 0 -
2 a - 0 -
2 b - 0 -
2 c - 0 -
3 a - 2 -
3 b - 0 -
3 c - 3 -
4 - 5 -
1 Calculated by Student’s independent t-test. 2 Federation of International of Gynecologists and Obstetricians.
2.2. Plasma ESI-LC–MS Based Metabolomic Analyses
In metabolites, we used the AbsoluteIDQ® p400 HR Kit (Biocrates Life Science AG, Innsbruck,
Austria) for absolutely quantifying 408 metabolites in the plasma samples. Quality control was
performed according to the Biocrates manufacturer’s sample measurement method (Innsbruck,
Austria), and metabolite quantitation data were filtered based on the limit of determination (LOD)
and the limit of quantification. Then, we absolutely quantified 199 metabolites, 20 amino acids,
7 biogenic amines, 1 monosaccharide, 16 acylcarnitines (AC), 13 diglycerides (DC), 30 triglycerides,
9 lysophosphatidylcholines (LPS), 63 phosphatidylcholines (PC), 25 sphingomyelins (SM), 4 ceramides,
and 10 cholesteryl esters (Figure 1A and Table S1). Two groups were clearly segregated by principle
components 1 (35.6%) and 2 (16.1%; Figure 1B). To find the differentially abundant plasma metabolites
(DAMs), fold-changes and Bonferroni-corrected p-values (q-value) were calculated by Student’s t-test
analysis of the two groups. A volcano plot showing log2-fold-changes against minus log10 p-values
identified 34 metabolites as being upregulated in the HC (q-value < 0.05; Figure 1C and Table S1).
The pathway enrichment analysis based on metabolite quantitative alterations was performed by the
MetaboAnalyst 4.0 (http://www.metaboanalyst.ca) [26] (Figure 1D). The HC-upregulated proteins
were highly involved in “Taurine and hypotaurine metabolism”, “Primary bile acid biosynthesis”,
“Glycerophospholipid metabolism”, and “Tryptophan metabolism”. In addition, to confirm the
diagnostic ability, we performed univariate receiver operating characteristic (ROC) analysis of
metabolites against the occurrence of ovarian cancer (Figure 1E and Table S2). In the results,
116 metabolites were significant (p < 0.05), and 36 metabolites represented more than 0.95 of the area
under the curve (AUC) value.
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Figure 1. Targeted metabolic analysis by mass spectrometry in the clinical plasma samples. (A) Donut
plot of 199 quantified metabolites in the AbsoluteIDQ p400 kits; (B) PCA analysis result of plasma
metabolites in 20 clinical samples; (C) volcano plot of plasma metabolic data; volcano plots are depicted
with the fold change of each metabolic amount and the p value was calculated by performing a Student’s
t-test. Blue circles are less than a Bonferroni-corrected p-value < 0.05, indicating a significantly increased
34 metabolites in HC. Gray circles are plasma metabolites without statistical meaning. (D) Pathway
enrichment analysis in the MetaboAnalyst 4.0 tool; the y-axis represents the p value, the x-axis represents
the impact value; the top five pathways are represented as text based on the p-value. The color and
size of each circle represents p-values and pathway impact values, respectively. (E) Histogram of 199
absolute area under curve values in univariate ROC analysis. Red bar indicates the high mean value in
ovarian cancer and the blue bar indicates the low mean value.
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2.3. Plasma ESI-LC–MS/MS Proteomic Analyses
A total of 1289 proteins were identified in a total of 20 LC–MS/MS measurements (Figure 2A).
By label free quantification (LFQ), we eliminated proteins bound to the MARS14 affinity column
and measured less than three times in one group, then we selected filtered 1124 proteins that
were normalized by width adjustment and missing value imputation and we performed principle
component analysis (PCA) analysis (Figure 2B and Table S3). Similarly, we applied the above-mentioned
metabolite statistical analysis to 1124 proteins to discover the differential abundant plasma proteins
(DAPs) and we identified 108 proteins as being upregulated in the OC and 89 proteins in the HC
(Bonferroni-corrected p < 0.05; Figure 2C and Table S4). By using g:Profiler [27], the Reactome pathways,
which differed significantly between the two groups, are shown in Figure 2D. The OC-upregulated
plasma proteins were enriched in the eight functional categories. First, platelets are known to increase
ovarian cancer growth or activate metastasis [28–32], and functional terms related to this include
“Platelet degranulation”, “Response to elevated platelet cytosolic Ca2+”, and “Platelet activation,
signaling, and aggregation”. Second, the immune response in the tumor environment around ovarian
cancer is related to the patient’s prognosis [33,34], and related terms include “Immune System”,
“Innate Immune System”, “Neutrophil degranulation”, and “Attenuation phase. Third, it is related
to the mechanisms related to the energy metabolism of ovarian cancer [35–37], and the related term
is “Gluconeogenesis”. Fourth, “Hemostasis” has been linked to ovarian cancer [38,39]. Fifth, it is
known that ovarian smooth muscle tumors and ECM-related proteins regulate the cancer environment,
and related terms are “Cell–extracellular matrix interactions” and “Smooth Muscle Contraction”.
Sixth, ovarian cancer that responds to external stimuli or stress causes “HSF1 activation” and “cellular
response to heat stress” [40–43]. Seventh, there are terms “Activation of BAD and translocation to
mitochondria” and “Signaling by Hippo” as the mechanisms involved in cancer and the surrounding
normal cells for signaling for ovarian cancer survival [44–47]. Finally, the terms “Signaling by Rho
GTPases”, “EPHB-mediated forward signaling”, and “RHO GTPase Effectors” related to cross-talk
between Ras and Rho signaling, well known as ovarian cancer signaling, were enriched [48–50].
The HC-upregulated proteins were highly involved in “Post-translational protein phosphorylation”,
“Neutrophil degranulation”, “Regulation of Insulin-like Growth Factor (IGF) transport and uptake
by IGF Binding Proteins”, “Innate Immune System”, “Immune System”, and “Extracellular matrix
organization”. Most of these terms were also elevated in ovarian cancer patients except for the
IGF-related function, which was related to the risk of ovarian cancer [51,52]. Then, we performed
univariate ROC analysis of proteins against the occurrence of ovarian cancer (Figure 2E and Table S4).
We found 702 proteins were significant (p < 0.05), and 161 proteins represented more than 0.95 of the
AUC value.
2.4. Ingenuity Pathway Analysis (IPA) of the Integrated Metabolites and Proteins
The 199 quantified metabolites and 197 DAPs were used for integration analysis in IPA.
As a result of canonical pathway analysis, the top five significantly different pathways were
“tRNA Charging”, “Remodeling of Epithelial Adherens Junctions”, “Integrin Signaling”, “RhoA
Signaling”, and “Superpathway of Citrulline Metabolism” (Table S5). In the network function analysis,
IPA identified 15 highly enriched pathway networks (Table S6). Then, we applied the Molecular
activity predictor in IPA to predict the consequences of these pathway changes for biological function.
Three networks (Network #1, #5, and #12) were linked to EGFR/ERBB2 signaling pathways that are
well-known to have a major role in ovarian cancer [53–55] (Figure 3). It can be inferred that the EGFR
signal is inactivated, and the ERBB2 (alternative gene name: HER2) signal is activated while NFkB is
activated to promote tumor-cell proliferation and survival [56–58]. Network #2 represents a general
cancer signaling pathway from hypoxia-inducible factor 1 (HIF-1) under tumor hypoxia, and it is known
that targeting this network could overcome anticancer drug resistance [59,60]. Network #3 represented
reduced TGFBI abundance to derive the PI3 K/AKT pathway inhibition, a common manifestation
in cancer [61], and the JAK/STAT signaling pathway, which is proposed as a new target for ovarian
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cancer anticancer drug resistance [62,63], is dysregulated in network #8 and other signaling pathways
associated with ovarian are shown in Figure S1.
Figure 2. Proteomic analysis by LC–MS/MS. (A) The number of identified proteins in the two groups
(control and disease); (B) PCA analysis result of the plasma proteins; (C) volcano plot of the plasma
proteomic data; red circles are less than the Bonferroni corrected p-value < 0.05, indicating a significantly
increased 108 proteins in OC. Blue circles are less than a Bonferroni-corrected p-value < 0.05, indicating a
significantly increased 89 proteins in HC. (D) Reactome pathway enrichment analysis; red bar indicates
that the pathways were enriched in the upregulated proteins in OC, and blue indicates that the pathways
are enriched in the upregulated proteins in HC. The size of the bar is the Q value. (E) Histogram of
1124 absolute area under curve values in univariate ROC analysis.
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Figure 3. Merging network associated with the EGFR/ERBB2 signaling pathway by IPA-identified three
networks (#1, #5, and #12 in Table S6). EGFR and ERK1/2 are weakly downregulated, and NFKB1 and
ERBB2 are strongly upregulated in ovarian cancer patients. The network shapes show the categories of
the proteins. In the IPA network, red indicates ovarian cancer upregulation, green, downregulation,
orange, predicted upregulation, and blue, predicted downregulation and the color intensity indicates
the magnitude of the relative change in protein expression.
2.5. Integration Analysis for Discovering Clinical Markers
Assuming a null correlation between the proteome and metabolome, we incorporated two
biomolecular domains by using sparse multiblock partial least square discriminant analysis in Data
Integration Analysis and Biomarker discovery using Latent cOmponents (DIABLO) [64]. A heatmap of
two-dimensional biomolecules is displayed in Figure 4A. A correlation plot between the abundances
of the metabolites and proteins is shown in Figure 4B. Polar lipids, LPC and PC were highly correlated
with 24 proteins (|r| > 0.9), which function in cadherin binding, were located in focal adhesion,
cell-substrate junction, and extracellular vesicles by analyzing g:Profiler [27] (Figure 4B). To overcome
the small sample size bias, we compared the DAMs in several other metabolic biomarker studies
(Table 2). In the other two blood-derived ovarian cancer studies [9,11], similar to the results of this
study, the abundances of two types of polar lipids, LPC and PC, were generally significantly lower in
ovarian cancer patients. In particular, the amount of LPC (18:0) showed the same pattern in all three
studies. Otherwise, in metabolic analysis studies in tissues [8], the amount of polar lipids and taurine
were significantly high as opposed to in the blood samples.
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Figure 4. Multiomics combined analysis of metabolome and proteome. (A) Heatmap of hieratical
clustering of 34 DAMs and 197 DAPs in the two groups (control and disease); (B) Diagram of the
correlation between DAMs and DAPs with a correlation between them with an absolute value of 0.9
or higher. (C) Blocked sparse PLA-DS analysis of metabolites and proteins that divide the control,
stage 3, and stage 4 groups; (D) Scatter plot of the 1st component of the proteome and metabolome in
the three groups; the second component also appears the same. (E) Heatmap of hieratical clustering of
eight metabolites and proteins contributing to components 1 and 2, respectively; (F) Diagram of the
correlation between eight metabolites and eight proteins contributing to component 2 with a correlation
between them with an absolute value of 0.444 or higher.
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Table 2. Meta-analysis of DAMs with already published studies.
Name
Current Study Plasma [11] Plasma [9] Tissue [8]
FC (OC/HC) p FC (OC/HC) p FC (OC/HC) p FC (OC/HC) p
Ornithine 0.55 1.85 × 10−6 - - - - 4.00 1.00 × 10−4
Tryptophan 0.50 7.68 × 10−5 − - - - 2.42 1.00 × 10−4
Spermidine 0.17 6.26 × 10−6 - - - - 2.25 3.00 × 10−4
Taurine 0.22 6.14 × 10−8 - - - - 3.00 4.00 × 10−4
AC(10:0) 0.32 9.09 × 10−5 - - - - - -
AC(16:0) 0.58 1.82 × 10−4 - - - - - -
AC(18:2) 0.44 2.47 × 10−6 - - - - - -
DG-O(36:4) 0.67 4.65 × 10−5 - - - - - -
LPC(16:0) 0.40 1.34 × 10−7 - - - - 1.00 2.23 × 10−2
LPC(18:0) 0.36 7.58 × 10−7 0.74 8.77 × 10−3 0.74 2.00 × 10−4 1.50 2.43 × 10−2
LPC(18:1) 0.44 2.29 × 10−6 - - 0.72 2.90 × 10−5 1.50 2.43 × 10−2
LPC(18:2) 0.45 5.15 × 10−5 - - - - 2.00 2.65 × 10−2
LPC(20:4) 0.49 1.38 × 10−4 - - - - 1.00 2.88 × 10−2
LPC-O(16:1) 0.34 5.65 × 10−9 - - - - - -
LPC-O(18:1) 0.34 5.85 × 10−7 - - - - - -
LPC-O(18:2) 0.41 9.80 × 10−9 - - - - - -
PC(32:2) 0.40 1.47 × 10−4 0.59 7.70 × 10−5 - - - -
PC(33:2) 0.47 1.35 × 10−4 - - - - - -
PC(34:2) 0.63 2.37 × 10−5 - - - - - -
PC(35:3) 0.48 7.74 × 10−8 - - - - - -
PC(36:2) 0.60 3.41 × 10−5 0.81 1.29 × 10−2 - - - -
PC(36:3) 0.59 3.55 × 10−6 - - 0.87 1.47 × 10−2 - -
PC(37:5) 0.48 1.30 × 10−6 - - - - - -
PC(40:4) 0.61 3.49 × 10−6 - - - - - -
PC(41:3) 0.35 7.60 × 10−6 - - - - - -
PC(41:4) 0.47 4.75 × 10−5 - - - - - -
PC(41:5) 0.57 1.56 × 10−4 - - - - - -
PC-O(34:2) 0.51 2.05 × 10−6 0.76 9.59 × 10−3 - - - -
PC-O(34:3) 0.44 4.87 × 10−7 - - - - - -
PC-O(36:3) 0.52 4.92 × 10−6 0.75 1.76 × 10−3 - - - -
PC-O(36:5) 0.60 1.89 × 10−4 - - - - - -
SM(32:1) 0.58 1.08 × 10−4 - - 0.66 9.70 × 10−3 - -
SM(39:1) 0.55 1.14 × 10−4 - - - - - -
SM(41:2) 0.64 1.65 × 10−4 - - - - - -
In proteins, unlike metabolites, some of the proteins overexpressed in ovarian cancer tissues could
be released into the plasma [65], and in this respect, we examined whether DAPs are differentially
expressed in ovarian cancer tissues. In a recent study [23], they integrated the proteogenomic signature
from the high-grade serous ovarian cancer tissues. Our 137 proteins out of 197 DAPs were subjected
to Kaplan–Meier (KM) analysis in terms of overall survival (OS; n = 169), disease-free survival (DFS;
n = 145), and platinum-free interval (PFI; n = 126). Independently, 61 proteins in 5-year OS analysis,
74 proteins in 5-year DFS survival analysis, and 56 proteins in PFI were significant. Among them,
24 proteins, namely ACTR2, ANPEP, ANXA5, ARF3, ARHGDIA, ARPC4, COPB1, CRP, ENO1, DPS,
GSTO1, ILK, LASP1, LDHA, MSLN, NEXN, PDIA4, PDLIM5, PTPRG, SERPINC1, TAGLN, TAGLN2,
TPM3, and TPM4 were commonly statistically significant in the three survival analyses. Unfortunately,
ovarian cancer blood protein markers mainly consist of antibody-based methods with a focus on
CA-125 and there are fewer than five markers, so there was no comparable data with more than a
hundred proteins [66–70].
Patients with stage 4 ovarian cancer have metastases to other organs. To find the features
from biomolecules, we divided the ovarian cancer into different stages and performed DIABLO
analysis in three groups (control, stage 3, and stage 4) and built a horizontal integration partial
least squares-discriminant analysis model (Figure 4C). Its first component classified the control and
disease and its second component classified stage 3 and stage 4 regardless of the control (Figure 4D).
Two components contained the eight metabolites and proteins selected for each on the heatmap
(Figure 4E). Correlation analysis was performed by focusing on proteins and metabolites with a second
component that divided stages 3 and 4, which differentiated cancer metastasis, and this is shown as a
circus plot (Figure 4F). Three proteins, phosphopantothenate-cysteine ligase (PPCS), myelin P2 protein
(PMP2), and tubulin beta chain (TUBB), were significantly correlated with L-carnitine (AC.0.0) and PC-O
(30:0). The carnitine system is related to cancer metabolic plasticity [71] and acetylation of carnitine
facilitates myelination of regenerated axons after peripheral nerve injuries with physical binding to
PMP2 and TUBB [72]. In order to validate prognostic protein marker candidates, survival analysis
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was performed on the webpage Kaplan–Meier plotter (KM plotter, http://kmplot.com/) with mRNA
expression and a progression-free survival (PFS) period [73] for 1232 serous ovarian cancer patients.
The proteins were not mapped to the above ovarian tissue protein survival analysis. Anyway, based on
the 5-year PFS, CALML5, ITGA2 B, PMP2, PPCS, and TUBB out of eight genes in the second component
were statistically significant in two subtypes as low or high risk groups (hazard ratio (HR), 1.31,
1.16, 1.29, 0.78, and 1.36; log-rank test: p < 0.05). Among them, only two genes, PPCS and TUBB,
matched the risk in the same direction in the amount of plasma and mRNA as the disease progressed
(Figure 5A–C). In addition, TUBB also showed statistical significance against 5-year overall survival
(HR, 1.58; log-rank test: p < 0.05; Figure 5D).
Figure 5. Boxplot and survival curves of two genes (PPCS and TUBB) selected as prognostic markers
candidates. (A) A boxplot for the protein normalized abundances of two proteins in three groups
obtained in this study; (B) Kaplan–Meier plot of PPCS (Probe set image ID: _at) in progression-free
survival (PFS); (C) survival curve of TUBB (Probe set image ID: _at) in PFS; (D) survival curve of TUBB
in overall survival (OS).
3. Discussion
In the current study, metabolite biomarker candidates are generally reduced in the plasmas of
ovarian cancer patients. Plasma deprivation of them is indirect evidence that ovarian cancer cells
consumed these metabolites supplied from the blood. The process of absorbing the metabolites
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necessary for the growth of cancer cells supplied from the culture supplement was demonstrated
in vitro [74–76]. Releasing taurine occurred in ovarian cancer cells sensitive to cisplatin [77].
Tryptophan is used for direct catalytic reactions of oncogenic enzyme, which is a tryptophan-degrading
enzyme indoleamine 2,3-dioxygenase, immunoescape mechanism of tumor cells [78,79]. Likewise,
ornithine decarboxylase launches the polyamine biosynthetic pathway by using ornithine, and is
activated with high expression in cancer cells to increase the susceptibility of tumor development
to changes in polyamine levels and by transforming the response to cytokines, abnormal oncogenic
gene expression, and tumor promoter mutations [80,81]. Spermidine, a polyamine compound,
could suppress the cancer cells by inducing autophagic apoptosis activation [82,83] but is found at
lower levels in ovarian cancer patients’ plasmas. The alteration of lipids including LPC, PC, and SM
cause ovarian carcinogenesis, and the risk of ovarian cancer with plasma lipids has been identified [84].
LPC is a bioactive proinflammatory lipid produced by pathological activities [85] and rewired storage
and metabolism in ovarian cancer cells after treating with anti-VEGF agents [86]. PC is a major
component of biological membranes and plays a role in cell proliferation and survival [87]. It has
been reported that the alteration of PC metabolism in cancer cells is a signature of tumor progression
and could be a target for anticancer agents [88]. In particular, the aberrant reaction is triggered by
phospholipase C activation in epithelial ovarian cancer cells [89,90]. SM consists of a phosphocholine
head group and ceramide contained sphingosine and fatty acids and its subcellular location is correlated
with cholesterol [91]. It is important to acquire a resistance to anticancer agents since ovarian cancer
cells provoke an aberrant SM mechanism that involves the promotion of the catabolism of ceramide,
and the production and accumulation of ceramide [92,93].
In the study of biomarker discovery in blood, many researchers have tried to explain the causal
relationship with disease by identifying their biological function using differential abundant molecules.
Interestingly, in this study, it was found that the interpretation of the cancer signaling pathways
contrasts with the network analysis using only the protein and the analysis involving metabolites.
Between the two analysis results, the activation of NFkB, ERK1/2, estrogen receptor, and HIF-1 signaling
pathways had the opposite results, except for the ERK and AKT signaling pathway. This result may
reveal a blind spot in the analysis of widely used blood protein-based disease-associated pathways.
On the other hand, by integrating metabolites and proteins, this multiomics analysis aimed to find
emerging properties that were difficult to see in a one omics approach. Through the comparative
analysis function of IPA, we discovered key emerging pathway upstream regulators that were indicators
for discovering new drug targets, and toxicological analysis showed that the patient’s liver, heart,
and renal function was damaged. One of the emerging canonical pathways is “Glutathione-mediated
Detoxification” (activation z-score: -0.447) in which glutathione is involved in the regulation of ROS
in cancer progression [94]. In the new drug target discovery, it was found that ERBB2 is activated
in patients with ovarian cancer, and for BMS-, pirotinib, allitinib, poziotinib, erlotinib, sapitinib,
osimertinib, lapatinib, nordihydroguaiaretic acid, and afatinib (activation score > 0.7), which can
inhibit ERBB2, were found among upstream regulators found only in the integrated analysis.
This retrospective study focused on the metabolic and proteomic analysis of OC patients, and it
has several limitations. The patient population was homogenous, enrolled at a single-center and of a
small sample size. Plasma markers in patients with stage 3–4 might have divergent trends according
to the character of peri- or postoperative adjuvant therapy. Therefore, these results require further
validation in multicenter cohorts including larger numbers of patients to evaluate their applicability to
broader populations with ovarian cancer.
4. Materials and Methods
4.1. Sample Subjects
All plasma specimens in this study were obtained with appropriate consent and approval
of the institutional review board of Yonsei University Gangnam Severance Hospital (IRB number:
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3–2018-0166, approved on 18 July 2018). All data were collected anonymously. This study was exempt
from obtaining informed consent by the IRB committee. Plasma samples were obtained preoperatively
from 10 OC patients and 10 female HC subjects and provided by the Korea Gynecologic Cancer Bank
through Bio and Medical Technology Development Program of the Ministry of the National Research
Foundation (NRF) funded by the Korean government (MSIT) (NRF-2017 M3 A9 B). The clinical data of
the 20 participants are summarized in Table 1. All samples were frozen in liquid nitrogen and were
stored at −80 ◦C until analysis.
4.2. Metabolite Analysis
The targeted metabolomics evaluation used electrospray ionization liquid
chromatography–tandem mass spectrometry (ESI-LC–MS/MS) and flow injection analysis–tandem
mass spectrometry (FIA–MS/MS) techniques with the AbsoluteIDQ™ p400 kit (BIOCRATES
Life Sciences AG, Innsbruck, Austria) to analyze 10 µL of plasma from each patient. The assay
allows for simultaneous quantification of 408 metabolites out of 10 µL plasma, including 21
amino acids (19 proteinogenic amino acids, citrulline and ornithine), 21 biogenic amines, hexose
(sum of hexoses—about 90–95% glucose), 55 acylcarnitines, 18 diglycerides, 42 triglycerides,
24 lysophosphatidylcholines and 172 phosphatidylcholines, 31 sphingolipids, 9 ceramides, and 14
cholesteryl esters (Table S1). Plasma samples (10 µL), blanks, calibration standards, and quality controls
were prepared according to the manufacturer’s manual instructions. All amino acids and biogenic
amines were derivatized with phenylisothiocyanate and quantified by multiple reaction monitoring
(MRM) techniques with internal standards. MRM–MS analyses were carried out on an API 4000
LC–MS/MS System (AB Sciex Deutschland GmbH, Darmstadt, Germany) equipped with a 1200 Series
HPLC (Agilent Technologies Deutschland GmbH, Boeblingen, Germany) controlled by the Analyst
1.5.1 software. Otherwise, the remaining 366 metabolites were measured by FIA–MS/MS which were
analyzed on a Thermo Scientific UltiMate 3000 Rapid Separation Quaternary HPLC System (Thermo
Scientific, Madison, WI, USA), connected to a QExactive™ Plus Hybrid Quadrupole-Orbitrap™Mass
Spectrometer (Thermo Scientific, Waltham, MA, USA). Following this, the concentrations of the
metabolites were generated by Biocrates MetIDQ software. The quality control of the experiment was
also validated using the Biocrates software (version 5, MetIDQ, Biocrates, Innsbruck, Austria).
4.3. Proteomic Sample Preparation
Plasma samples were sequentially prepared by high abundant plasma protein depletion and
trypsin/Lys-C digestion steps. At first, we depleted the high abundant plasma proteins by a Multiple
Affinity Removal Column Human 14 (100 × 4.6 mm; MARS14, Agilent, CA, USA) column equipped
in the HPLC systems. We digested the proteins to peptides by the amicon-adapted enhanced
FASP method [95] and salts were removed sequentially by the C18 desalting cartridge (Sep-Pak
C18 1 cc, Waters, USA). First, 40 µL of plasma was injected into the MARS14 depletion column in
which the top 14 abundant proteins (albumin, IgA, IgG, IgM, a1-antitrypsin, a1-acid glycoprotein,
apolipoprotein A1, apolipoprotein A2, complement C3, transferrin, a2-marcoglobulin, transthyretin,
haptoglobin, and fibrinogen) were depleted. For this, the mixture was 4-fold diluted with a proprietary
“Buffer A” and loaded onto a MARS14 column on a Shimadzu HPLC system. The unbound fraction
was buffer-exchanged into 8 M urea in 50 mM Tris (pH 8) and 20 mM dithiothreitol and concentrated
through ultrafiltration using a Vivaspin 500 3 kDa cutoff filter (Sartorius, Goettingen, Germany) to
approximately 50 µL and then transferred to a new filter unit (Nanosep, 30 kDa; Pall Corporation, NY,
USA). We added 200 µL of 8 M urea in 50 mM Tris (pH 8.5) and centrifuged it at 14,000× g for 15 min
repeated twice. We discarded the flow-through from the collection tube. We then added 100 µL of
iodoacetamide solution and mixed it at 600 rpm in a thermo-mixer for 1 min and incubated it without
mixing for 20 min. We centrifuged the filter units at 14,000× g for 10 min. Then, we added 100 µL of
8 M urea in 100 mM ammonium bicarbonate (ABC) to the filter unit and centrifuged it at 14,000× g for
15 min. We repeated this step twice. Then, we added 100 µL of ABC to the filter unit and centrifuged it
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at 14,000× g for 10 min. We repeated this step twice. We added 40 µL ABC with Lys-C/trypsin (enzyme
to protein ratio 1:25) and mixed it at 600 rpm in a thermo-mixer for 1 min. We incubated the units in a
wet chamber at 37 ◦C for 12 h. We transferred the filter units to new collection tubes and centrifuged
the filter units at 14,000× g for 10 min. Then, we added 40 µL of 0.5 M NaCl and centrifuged the filter
units at 14,000× g for 10 min. Formic acid was then added to a final concentration of 0.3% to stop the
digestion reaction. The peptide mixture was then desalted with a Sep Pak C-18 cartridge (Waters,
Milford, MA, USA), lyophilized with a cold trap (CentriVap Cold Traps, Labconco, Kansas City, MO,
USA) and stored at −80 ◦C until use.
4.4. Nano-LC-ESI–MS/MS Proteomic Analysis
Digested peptides were separated using a Dionex UltiMate 3000 RSLCnano system (Thermo
Fisher Scientific). Tryptic peptides from the bead column were reconstituted in 0.1% formic acid and
separated on an Acclaim™ Pepmap 100 C18 column (500 mm × 75 µm i.d., 3 µm, 100 Å) equipped
with a C18 Pepmap trap column (20 mm × 100 µm i.d., 5 µm, 100 Å; Thermo Scientific, USA) over
200 min (350 nL/min) using a 0–48% acetonitrile gradient in 0.1% formic acid and 5% DMSO for
150 min at 50 ◦C. The LC was coupled to a Q Exactive™ Plus Hybrid Quadrupole-Orbitrap™mass
spectrometer with a nano-ESI source. Mass spectra were acquired in a data-dependent mode with
an automatic switch between a full scan and 20 data-dependent MS/MS scans. The target value for
the full scan MS spectra, selected from 350 to 1800 mass to charge ratio (m/z), was 3,000,000 with
a maximum injection time of 100 ms and a resolution of 70,000 at m/z 400. The selected ions were
fragmented by higher-energy collisional dissociation in the following parameters: 2 Da precursor ion
isolation window and 27% normalized collision energy. The ion target value for MS/MS was set to
1,000,000 with a maximum injection time of 50 ms and a resolution of 17,500 at m/z 400. Repeated
peptides were dynamically excluded for 20 s. All MS data have been deposited in the PRIDE archive
(www.ebi.ac.uk/pride/archive/) [96] under Project PXD.
4.5. Protein Database Searching and Label Free Quantitation
The acquired MS/MS spectra were searched using the SequestHT on Proteome discoverer (version
2.2, Thermo Fisher Scientific, USA) against the SwissProt human database (1 May 2017). The search
parameters were set as default including cysteine carbamidomethylation as a fixed modification,
and n-terminal acetylation and methionine oxidation as variable modifications with two miscleavages.
Peptides were identified based on a search with an initial mass deviation of the precursor ion of up to
10 ppm, with the allowed fragment mass deviation set to 20 ppm. When assigning proteins to peptides,
both unique and razor peptides were used. Label-free quantitation (LFQ) was performed using peak
intensity for unique peptides of each protein [97].
4.6. Statistical Metabolomic and Proteomic Analyses
In the metabolomic data, 199 out of 408 metabolites were excluded from further analysis as they
exceeded the quality control (with no at zero concentration and concentrations below LOD in 10%
and below of all samples). In the proteome data, LFQ was performed with the missing data filling of
gaussian imputation separately for each column at parameter settings width = 0.3 and down-shift = 1.8
and normalization by width adjustment in the perseus software [98]. Data were analyzed using
RStudio (version 1.1.456) including R (version 3.6.0). Statistical R software packages included ggplot2
for drawing box and volcano plots, stats for calculating t-test, pROC for ROC analysis, mixOmics for
the integration of metabolic and proteomic data, drawing the heatmap, correlation and circus plots,
and pcamethods for PCA analysis.
4.7. Pathway Analysis
In the metabolomic data, DAMs in the OC and HC groups were analyzed using Pathway analysis
in the Metanalyst 4.0. We selected the parameters Over Representation Analysis: “Hypergeometric
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Test”, Pathway Topology Analysis: “Relative-betweeness Centrality”, Mammals: “Homo sapiens
(KEGG)”, and “Use all compounds in the selected pathways”. In proteomic data, molecular reactions of
DAPs in the OC and HC groups were annotated by g:Profiler. It was performed twice with a protein list
with significantly higher amounts for each group. The input data were the UniProtKB accession codes
of the proteins. We set the two parameters significance threshold: g:SCS, threshold: 0.05. Data sources
were selected by Reactome in the biological pathways. In the integration analysis, ingenuity pathway
analysis (Ingenuity System Inc, Redwood City, CA, USA) was used to carry out a core analysis of
the integrated 199 quantified metabolites and DAPs. In the uploaded data, the PubChem IDs for
metabolite and the UniProtKB IDs for the protein were entered, and both contained log2 fold-changes
between OC and HC. Based on the network results, an integrated analysis was performed using a
molecular activity predictor tool.
5. Conclusions
In this study, we integrated plasma metabolome and proteome data for discovering signatures of
high-grade serous ovarian cancer. Ovarian cancer-related signaling pathways were more confidently
interpreted by a multiomics approach beyond the limitations of single-omics analysis, and new drug
candidates were found.
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ROC Receiver operating characteristic
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